Overview
NNVC market data
Price History
NNVC price chart
Valuation & Profitability
No Valuation Data Yet
Alpha Vantage and Twelve Data both returned no valuation metrics for NNVC. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.
Company news
NanoViricides shares are trading lower after the company announced the pricing of its approximately $3.8 million offering of 2,516,339 shares.Benzinga · Jul 24, 2026, 12:34 PM
NanoViricides Prices ~$3.8 Million Registered Direct Offering Of 2,516,339 SharesBenzinga · Jul 24, 2026, 12:02 PM
NanoVricides Applies To DRC Regulatory Agency ACOREP For Approval To Begin A Phase II Clinical Trial Of NV-387 Oral Gummies To Treat The Current Bundibugyo EbolavirusBenzinga · Jul 22, 2026, 12:33 PM
8-K filing — NANOVIRICIDES, INC. (NNVC)SEC EDGAR · Jul 17, 2026, 8:45 PM
NanoViricides Gets National Ethics Committee Approval For Phase II Clinical Study Of NV-387 Oral Gummies To Treat Current Bundibugyo Ebolavirus In CongoBenzinga · Jul 13, 2026, 1:28 PM
Noble Capital Markets Initiates Coverage On Nanoviricides with Outperform Rating, Announces Price Target of $6Benzinga · Jul 6, 2026, 6:00 PM
NanoViricides Continues To Advance Broad-Spectrum Antiviral Drug NV-387 Towards Phase II Clinical Trial Of NV-387 Oral Gummies Formulation As Treatment For Current Bundibugyo Ebolavirus In DRCBenzinga · Jul 6, 2026, 12:45 PM
FDA's Office Of Orphan Products Development Grants Rare Pediatric Disease Drug Designation To NanoViricides' Antiviral Drug NV-387Benzinga · Jun 29, 2026, 12:45 PM
NanoViricides Ships NV-387 Oral Gummies To The Democratic Republic of Congo Ahead Of Patient Enrollment For Its Phase II Clinical Trial Of Monkeypox TreatmentBenzinga · Jun 22, 2026, 1:35 PM
NanoViricides' Proposal To Perform Phase II Clinical Trial Of NV-387 Oral Gummies As Treatment For Current Bundibugyo Ebolavirus Approved By Pillar Committee In Charge In DR CongoBenzinga · Jun 15, 2026, 12:45 PM